Key facts
- Cauldron Ferm’s last known valuation is $42.0M (Dec 2023).
- It has raised $30.3M; the latest was Early Stage VC ($13.3M) in Oct 2025.
- Notable investors include SOSV, United States Department of War, In-Q-Tel, Horizons Ventures, Main Sequence Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Cauldron Ferm
- ·The full record, as it builds
Funding rounds
No funding rounds for Cauldron Ferm are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cauldron Ferm
Developer of precision fermentation-based biomanufacturing processes intended to improve the cost efficiency and scalability of industrial production. The company's platform uses proprietary continuous hyper-fermentation technology, frequent high-volume harvesting and smaller, more efficient bioreactors, enabling industrial manufacturers to achieve lower-cost commercial-scale bioproduction
- Sector
- Healthcare
- HQ
- Borenore, Australia
- Founded
- 2022
- Employees
- 19
- Website
- cauldronferm.com/
- Ownership
- Privately Held (backing)
Cauldron Ferm doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cauldron Ferm shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cauldron Ferm in its N-PORT filings yet. We sweep new filings monthly.